Pharma major Dr Reddya’s Laboratories said on Saturday that after the launch of its generic Buprenophine and Naloxone Sublingual Film in the US market, the US district court of New Jersey issued a temporary restraint order and preliminary injunction against the company with regard to patent litigation. Pending a hearing and decision on the injunction application filed by Indivior Plc, the court issued a temporary restraint order against Dr Reddy’s with regard to further sales and commercialisation of the drug, which is used to treat adults with opioid dependence addition.
“The court order does not include prohibition on commercial manufacturing of the product. The plaintiffs will be required to post a bond or other security totalling $18 million to satisfy any losses or damages incurred by Dr Reddy’s during the period of the temporary restraint order,” Dr Reddy’s said in a statement on Saturday.
No comments:
Post a Comment